卵巢癌中的BRCA1表达及其与临床病理特征和预后的关系
Chenxiang Pan1, Shihao Xu2, Lijiao Li1
1Department of Gynaecology Oncology, Wenzhou Central Hospital, Wenzhou City, 325000, Zhejiang Province, China.
Scientific reports
|June 23, 2025
概括
乳腺癌易感性1 (BRCA1) 蛋白在卵巢癌中表达较低,与晚期和更差的预后相关. 在卵巢癌患者中,BRCA1表达是防止3年死亡的保护因素.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 卵巢癌的预后通常与临床病理特征有关.
- 乳腺癌敏感性1 (BRCA1) 在卵巢癌进展中的作用需要进一步阐明.
研究的目的:
- 调查BRCA1蛋白表达与卵巢癌临床病理特征之间的关联.
- 为了评估BRCA1在卵巢癌患者的预后意义.
主要方法:
- 使用免疫组织化学和临床蛋白质瘤分析联盟 (CPTAC) 数据库分析BRCA1蛋白表达的分析.
- 卡普兰-梅尔生存分析,以评估BRCA1表达和3年生存率之间的关系.
- 多变量考克斯回归分析以确定独立的预后因素.
主要成果:
- 与邻近组织相比,卵巢癌组织中的BRCA1蛋白质表达显着较低.
- 较低的BRCA1表达与先进的FIGO阶段 (III+IV),差异化和淋巴结转移相关.
- 阴性BRCA1表达与显著较低的3年生存率有关.
- 淋巴结转移是3年死亡率的独立风险因素,而BRCA1表达是保护因素.
结论:
- 在卵巢癌中,BRCA1的表达不足,并与不良的临床病理特征有关.
- 对于卵巢癌患者来说,BRCA1表达是一种有价值的预后标志物,表明它对死亡率起着保护作用.
更多相关视频
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.8K
08:53Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
14.8K
相关概念视频
01:20The Retinoblastoma Gene
4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
01:21Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458